The gut-brain axis is of great importance in the control of energy homeostasis. The identification of uroguanylin (UGN), an intestinal released peptide regulated by nutritional status and with anorectic actions, as the endogenous ligand for guanylyl cyclase 2C (GUCY2C) receptor, has revealed a new system in the regulation of energy balance. We show that chronic central infusion of uroguanylin (UGN) reduces weight gain and adiposity in diet-induced obese mice. These effects were independent of food intake and involved specific efferent autonomic pathways. On one hand, brain UGN induces brown adipose tissue thermogenesis as well as browning and lipid mobilization in white adipose tissue through stimulation of the sympathetic nervous system. On the other hand, brain UGN augments fecal output through the vagus nerve. These findings are of relevance as they suggest that the beneficial metabolic actions of UGN through the sympathetic nervous system do not involve non-desirable gastrointestinal adverse effects, such as diarrhea. The present work provides mechanistic insights on how UGN influences energy homeostasis and suggests that UGN action in the brain represents a feasible pharmacological target in the treatment of obesity.
After ingestion of a meal, the presence of nutrients in the gastrointestinal tract initiates complex neural and hormonal responses that signal to the brain about the ongoing changes in nutritional status. Among the different strategies to communicate to the brain, the gut secretes peptides that reach the central nervous system (CNS) via afferent nerve fibers or via the circulation (1; 2). New gut hormones are continuously discovered and with the exception of ghrelin, which is the only peptidic hormone favoring weight gain and adiposity, all of them are associated with a negative energy balance and are thus potential targets for the treatment of obesity (3; 4) .
One of the latest discovered gut hormones is uroguanylin (UGN), a 16 amino acid peptide secreted mainly from duodenal epithelial cells. UGN is synthesized as a prohormone (pro-uroguanylin), which after cleavage by a still unknown enzyme is converted to the active UGN (3; 5) . Both pro-UGN and UGN activate the guanilate cyclase 2C receptor (GUCY2C), which is also targeted by diarrheagenic bacterial heat stable enterotoxins (STs) (6) . The activation of GUCY2C lead to elevated intracellular levels of cGMP (7) , that in invertebrate species has been demonstrated to lead to alterations in food behavior and energy balance regulation (8; 9) . Circulating UGN levels were decreased in fasted and leptin-deficient mice, but recovered after refeeding or exogenous leptin infusion (10) , suggesting that UGN is regulated by nutritional status in a leptin-dependent manner.
A previous study proposed that the activation of GUCY2C is also relevant in the regulation of energy balance in mammals (11) . In mice, prouroguanylin is released from the gut immediately after nutrient intake and converted into active UGN within the hypothalamus, thereby activating GUCY2C and reducing food intake (11) . In agreement with these results, pharmacological stimulation of GUCY2C inhibited feeding in obese mice, and mice lacking GUCY2C are hyperphagic and more prone to develop metabolic syndrome (11) .
Despite the initial enthusiasm on UGN, these novel and promising findings have been recently challenged by another report indicating that the central administration of UGN or STs does not change food intake or body weight in lean rats and that GUCY2C knockout mice do not present variations in body weight or glucose metabolism when compared with their wild type (12) . In fact, that report only found a modest increase in body weight, adiposity and glucose intolerance when UGN deficient mice were fed a high fat diet (12) .
Since the precise role of UGN in the regulation of energy homeostasis is controversial and the pharmacological efficiency of UGN in obesity remains unknown, the aim of the present work was: 1) to investigate whether chronic exposure with UGN is an effective pharmacological treatment of obesity via its actions on important parameters in energy homeostasis, such as food intake, energy expenditure or nutrient partitioning; and 2) to dissect the molecular underpinnings involved in the metabolic action of UGN.
Research design and methods

Animals and diets
Swiss male mice (20- 
Several couples were then established from these homozygous mice at the University of Geneva, and experiments were performed on β 1 +/+ β 2
offspring. Food intake, body weight and total faeces mass were measured during the experimental phase in all experiments. Animals were killed by decapitation and tissues were removed rapidly and immediately frozen on dry ice and kept at -80ºC until their analysis. All experiments and procedures involved in this study were reviewed and approved by the Ethics Committee of the USC, in accordance with EU normative for the use of experimental animals.
Treatments and surgeries
Mice were anesthetized by an intraperitoneal injection of ketamine (8 mg/kg body weight) and xylazine (3 mg/kg of body weight). Intracerebroventricular (ICV) cannulae were implanted stereotaxically in mice, as described previously (16) . Animals received an ICV administration of vehicle (saline), α-MSH (3µg/mouse, Sigma-Aldrich, St.
Louis, MO) or UGN (10µg /mouse or 25µg /mouse, Bachem, Bubendorf, Switzerland).
To evaluate the chronic central effects of UGN, we connected a catheter tube from the brain infusion cannula to a osmotic micropump flow moderator (25µg/mouse/day).
Using blunt dissection, we created a subcutaneous pocket on the dorsal surface where we inserted the osmotic micropump (model 1007D, Alzet Osmotic Pumps, Durect, CA).
These pumps had a flow rate of 0.5 µl per hour during 7 days of treatment. After surgery mice were sutured and kept warm until fully recovered. For peripheral treatments, mice received an intraperitoneal administration of UGN (25µg/mouse).
Surgical vagotomy (VGX) was performed as previously described (17; Pharmacological inactivation of β3-AR was performed by subcutaneous (SC) administration of the specific antagonist SR59230A (Tocris Inc, USA) at a dose of 3mg/kg (19) .
Body composition and indirect calorimetry
Body composition (fat mass) was assessed using Nuclear Magnetic Resonance imaging system (Whole Body Composition Analyzer; EchoMRI, Houston, USA). Measurements were performed before surgery and the last day of the treatment. During the ICV treatment for the period of 7 days, mice were analyzed for energy expenditure, respiratory quotient (RQ) and locomotor activity using a calorimetry system (LabMaster; TSE Systems) (16) .
Protein extraction and Western Blot
Tissues were homogenized using a TissueLyser II (Qiagen, Tokyo, Japan) in cold RIPA 
Histomorphology
To study the histomorphological structure of BAT and WAT we performed hematoxylin/eosin staining in tissue sections. Briefly, BAT and WAT samples were fixed 24 hour in 10% formalin buffer and then were dehydrated and embedded in paraffin by a standard procedure. Sections of 3µm were made in a microtome and staining in a standard Hematoxilin/Eoxin Alcoholic (BioOptica) procedure following the manufacturer´s instructions (20) . Sections were observed and photographed using a Provis AX70 microscope (Olympus, Corp, Tokyo, Japan). Digital images for BAT were quantified with ImageJ Software (National Institutes of Health; USA).
Immunohistochemistry
Detection of UCP1 in BAT and WAT were performed using anti-UCP1 (1:500; Abcam, Cambridge, UK) as previously described (19) . Images were photographed with a digital camera Olympus XC50 (Olympus Corporation; Tokyo, Japan).
Real-time PCR
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RNA was isolated from the adipose tissue using Trizol® Reagent (Invitrogen,CA,USA)
according to the manufacturer´s instructions (18) . The extracted total RNA was purified with DNase treatment using a DNA-free kit as a template (Ambion, USA) to generate first-strand cDNAs using a high-capacity cDNA Reverse Transcription kit (Applied Biosystems, USA).Quantitative real-time PCR was performed using a StepOne Plus Instrument (Applied Biosystems) with specific Taqman qRT-PCR primers and probes.
The oligonucleotide specific primers are listed in Supplementary Table 1 . For the analysis of the data, HPRT was used as the endogenous control and the expression levels in the sample group was expressed relative to the average of the control group.
BAT Triglyceride Content
The extraction procedure for tissue triglyceride (TG) was adapted form methods described previously (13; 18). BAT was homogenized for 2 minutes in ice-cold chloroform-methanol (2:1), vol/vol). TGs were extracted during 5 hour shaking at room temperature. For phase separation, H2O Milli-Q was added, samples were centrifuged, and the organic bottom layer was collected. The organic solvent was dried ussing Speed
Vac and redissolved in chloroform. The TG (Randox Laboratories, LTD, London, UK) content of each sample was measured in duplicate after evaporation of the organic solvent using an enzymatic method.
Statistical Analysis
Results are expressed as mean ± standard error of the mean. GraphPad Prism (4.0) was used for the data analysis. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by a post hoc multiple comparison test (Bonferroni test).
A P-value less than 0.05 was considered statistically significant.
RESULTS
Acute central uroguanylin injection suppresses body weight independent of food intake in mice fed a high fat diet
We first injected two different doses of ICV UGN (10 and 25µg) in diet-induced obese (DIO) mice subjected to an overnight fasting. We found that a single ICV injection of UGN (25µg) significantly decreased food intake at 1, 2, 4 and 8h after injection, and then the effect diminished ( Figure 1A ). Although after 24h there were no differences in food intake, mice treated with ICV UGN at this dose showed a significant decrease in body weight when compared to ICV saline-treated mice ( Figure 1B ). At the lower dose UGN did not alter food intake ( Figure 1A ) or body weight ( Figure 1B ). As a positive control to corroborate the efficiency of the cannulae we also injected mice with ICV αMSH (3µg), which is known to inhibit feeding and body weight (21) . Next, we followed the same experimental protocol but in DIO mice fed ad libitum. Again the higher dose of ICV UGN (25µg) decreased food intake transiently ( Figure 1C ) and after 24h, ICV UGN-treated mice showed a significant inhibition of body weight gain in comparison to ICV saline-treated mice ( Figure 1D ). As expected, ICV αMSH also suppressed feeding and weight gain ( Figures 1C-1D ) in mice fed ad libitum.
To rule out the possibility that centrally injected UGN leaks out of the CNS into the circulation and elicits a response by directly acting at peripheral UGN receptors, we administered UGN peripherally at the same dose injected centrally (25µg). We were unable to detect changes food intake ( Figure 1E ) or body weight ( Figure 1F ). We therefore conclude that the effects observed during ICV administration were due entirely to UGN acting at central level.
Chronic central UGN infusion reduces adiposity independent of food intake in DIO mice
Central infusion of UGN (25µg/day) for 7 days did not affect cumulative food intake (Figure 2A ), whereas body weight gain was significantly lower from the day 2 to 7 of treatment ( Figure 2B ). In parallel to the decreased weight gain, fat mass gain was also significant lower in ICV UGN treated animals for 7 days compared to the control group 
Role of the vagus nerve in the central UGN control of gastrointestinal motility.
Vagal nerves regulate the physiological functions of the gastrointestinal (GI) tract (22).
Chronic central treatment of UGN increases faecal output in DIO mice ( Figure 2D ), and we next sought to determine if this effect involved vagal innervation. ICV UGN infusion was performed after dissections of both the dorsal and the ventral branches of the vagus nerve. The effectiveness of this approach was validated by assessing the expected morphological changes in the stomach (data not shown).
Central chronic UGN infusion did not affect food intake ( Figure 4A ), but significantly decreased body weight ( Figure 4B ) and fat mass ( Figure 4C ) in both sham operated mice and vagotomized (VGX) mice. The fecal output was increased in sham operated mice treated with UGN, but this effect was abolished in VGX mice ( Figure 4D ).
However, vagotomy did not blunt the effects of UGN on BAT as demonstrated by histological analyses that revealed smaller lipid droplets ( Figure 4E-4F ), decreased amount of TG in BAT ( Figure 4G ) and increased UCP-1 protein levels ( Figure 4H ) in BAT of both sham and VGX mice after 7 days of UGN treatment. Therefore, the present data suggest that vagal innervation is not involved in the thermogenic effect of UGN in BAT, however it seems to be directly related to UGN-induced increased fecal output.
Role of the SNS in the central UGN control of BAT and WAT metabolism.
Beta-adrenoreceptors (β-ARs) represent a key link involved in the regulation of adipose tissue metabolism by the SNS (19) . To determine if the central UGN action on BAT was mediated by SNS, triple (β1-AR, β2-AR and β3-AR) adrenoreceptor-deficient mice (TKO) were centrally infused with UGN for 7 days. UGN did not affect food intake neither in WT nor in TKO mice ( Figure 5A ). UGN significantly decreased body weight gain ( Figure 5B ) and fat mass gain ( Figure 5C ) in WT mice, but not in TKO mice. The lack of β-ARs did not appear to affect gastrointestinal function, as represented by the fact that UGN increased the fecal output in both WT and TKO mice ( Figure 5D ).
In BAT, the implication of the adrenergic innervation in the mediation of the effects of Figure 5H ). The lack of effects of central UGN on WAT of TKO mice was also evident when assessed by morphological approaches ( Figure 5I) and by the lack of changes in UCP-1 protein levels in epididymal WAT of UGN-treated TKO mice ( Figure 5J ).
The results obtained in TKO mice were corroborated by performing an acute pharmacological inactivation of the β3-AR with the specific antagonist SR59230A, which blunted the effect of ICV UGN on body weight 12h after its administration in DIO mice without affecting feeding behaviour (Figures 6A-6B ). Histological analyses showed that after 12h of the central injection of UGN, the size but not the number of lipid droplets was reduced ( Figures 6C-6D) , and the content of TG in BAT was also significantly lower than in ICV vehicle-treated DIO mice ( Figure 6E ). However, all the UGN-induced actions were blocked when animals were also treated with SR59230A. In line with this, the activation of BAT UCP-1 after central administration of UGN was also prevented by SR59230A ( Figure 6F ). Although the chronic effects of central UGN are independent of food intake, previous reports showed controversial results regarding the effects of the UGN-GUCY2C system on feeding. Whereas one report showed a decreased food intake 2h after the central injection of STs (11), a subsequent study failed to detect changes in food intake following administration of ST or UGN (12) . Similar to the first report (11), we found that ICV UGN (25 µg) transiently decreased feeding and that this effect was amplified by fasting. Moreover, we also found that chronic central infusion of UGN decreases weight gain in mice fed a chow diet or a HFD. The discrepancies between the studies might be related to different methodologies. For instance, our study uses both lean and obese mice, whereas that from Valentino et al (11) used obese mice, and the study from Begg et al (12) used lean rats.
DISCUSSION
Another very important aspect that deserves attention is the potential link between the UGN-GUCY2C system and a diarrheagenic function (32) . The reason for this is that GUCY2C is also the receptor for heat-stable enterotoxin that is responsible for acute diarrhea (6) . For instance, linaclotide, a synthetic peptide that is structurally related to the endogenous guanylin peptide family, activates GUCY2C and is clinically used for chronic constipation (33) . Consistent with this, our results indicate that central UGN increases fecal output. The subdiaphragmatic vagal nerve and its branches innervate the gastrointestinal tract, and the extensive distribution of vagal nerves to the gut plays an important role in the regulation of many digestive functions including gastric accommodation and gastrointenstinal motility (22) . Therefore, we assessed the contribution of UGN-induced gastrointestinal motility to the reduced weight gain and adiposity. Treatment with CNS UGN was performed in animals subjected to surgical VGX, and we found that UGN failed to affect fecal output. In VGX mice treated with central UGN the effects on body weight and fat mass were only partially abolished, likely because its thermogenic effect was still active. Thus, we can conclude that the parasympathetic nervous system is mediating the gastrointestinal effects of CNS UGN but that it is not involved in the effects on adipose tissue metabolism.
In summary, the present work reveals for first time that chronic central UGN infusion decreases body weight and adiposity in DIO mice independent of food intake via Values are represented as mean ±SEM; n=10-11 animals per group. *P < 0.05, **P < 0.01; ***P <0.001 vs vehicle. UGN, uroguanylin; EE, energy expenditure; RQ, respiratory quotient. 
